Ortin Global Ltd (ORTINGLOBE) — shareholding pattern, promoter holding, financials and share price
About Ortin Global Ltd (ORTINGLOBE)
Ortin Global Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ORTINGLOBE and on the BSE under scrip code 539287. Its ISIN is INE749B01020.
Incorporated in 1986, Ortin Laboratories Ltd manufactures pharmaceutical formulations. [1]
Ortin Laboratories Limited is a leading pharmaceutical manufacturer in India, specializing in a wide range of pharma formulations including tablets, capsules, syrups, and ointments.
The company has strategically expanded its manufacturing capabilities and geographical reach by obtaining certifications for exports to Asian, African, and Middle East countries.
Listed peers in Pharmaceuticals: Zenith Health Care Ltd, Dipna Pharmachem Ltd, Starsource Multitrade Ltd, Saroja Pharma Industries India Ltd, Beryl Drugs Ltd, Unjha Formulations Ltd.
Valuation & Returns
10 Jul 2026At ₹17.3 a share on 10 Jul 2026, Ortin Global Ltd (ORTINGLOBE) was valued at a price-to-earnings ratio of -19.01x against an industry P/E of 36.41x and a price-to-book of 7.11x on a book value of ₹2.43 per share as of Mar 2025. Solomo computes return on equity of -37.42% and return on capital employed of -32.32% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -19.01x
- Industry P/E
- 36.41x
- P/B
- 7.11x
- EPS (TTM)
- ₹-0.91
- Book value / share
- ₹2.43
- ROE
- -37.42%
- ROCE
- -32.32%
- ROA
- -19.57%
- Debt / equity
- 0.13x
- Dividend yield
- 0%
- EBITDA margin
- -800%
- 52-week range
- ₹11.18 – ₹21.15
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Ortin Global Ltd (ORTINGLOBE) reported revenue of ₹0.41 crore, net profit of ₹-0.74 crore and earnings per share of ₹-0.91. That compares with revenue of ₹0.34 crore and net profit of ₹-0.85 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Jun 2012, revenue was ₹15.93 crore and net profit ₹0.44 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 8.23 | 6 | 2.01 | 0.34 | 0.41 |
| Net profit (₹ cr) | -0.4 | -0.09 | -8.04 | -0.85 | -0.74 |
| EPS (₹) | -0.49 | -0.11 | -9.89 | -1.05 | -0.91 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -44.38% | -71.96% | -65.36% | -83.89% |
| Profit growth | - | - | - | 89.43% |
| Stock price CAGR | 0% | -15% | -8% | 37% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 1.23% of Ortin Global Ltd (ORTINGLOBE) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.8%. Market capitalisation was ₹14 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2015.
Largest disclosed public shareholders in Jun 2026: SURESH GADALAY 6.35%, RAJESH PODDAR 4.69%, MIR ATA ALI KHAN 2.65%, HUF 1.75%, NALLAVOLU JAYAMMA 1.69%, WAVE CAPITAL LTD 1.68%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 1.23% | - | 1.8% | - | 98.77% |
| Mar 2026 | 1.23% | - | 1.68% | - | 98.77% |
| Dec 2025 | 1.23% | - | 1.68% | - | 98.77% |
| Sep 2025 | 1.23% | - | 1.68% | - | 98.77% |
| Jun 2025 | 1.23% | - | 6.53% | - | 98.77% |
| Mar 2025 | 1.23% | - | 6.53% | - | 98.77% |
| Dec 2024 | 1.23% | - | 6.25% | - | 98.77% |
| Sep 2024 | 1.23% | - | 6.25% | - | 98.77% |